Cargando…

Impaired myelination and reduced brain ferric iron in the mouse model of mucolipidosis IV

Mucolipidosis type IV (MLIV) is a lysosomal storage disease caused by mutations in the MCOLN1 gene, which encodes the lysosomal transient receptor potential ion channel mucolipin-1 (TRPML1). MLIV causes impaired motor and cognitive development, progressive loss of vision and gastric achlorhydria. Ho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grishchuk, Yulia, Peña, Karina A., Coblentz, Jessica, King, Victoria E., Humphrey, Daniel M., Wang, Shirley L., Kiselyov, Kirill I., Slaugenhaupt, Susan A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Company of Biologists 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4728313/ https://www.ncbi.nlm.nih.gov/pubmed/26398942 http://dx.doi.org/10.1242/dmm.021154

Ejemplares similares

Early evidence of delayed oligodendrocyte maturation in the mouse model of mucolipidosis type IV
por: Mepyans, Molly, et al.
Publicado: (2020)

Cross-sectional Observations on the Natural History of Mucolipidosis Type IV
por: Misko, Albert L., et al.
Publicado: (2022)

Peripheral Inflammatory Cytokine Signature Mirrors Motor Deficits in Mucolipidosis IV
por: Misko, Albert L., et al.
Publicado: (2022)

Behavioral deficits, early gliosis, dysmyelination and synaptic dysfunction in a mouse model of mucolipidosis IV
por: Grishchuk, Yulia, et al.
Publicado: (2014)

Proteomics analysis of a human brain sample from a mucolipidosis type IV patient reveals pathophysiological pathways
por: Vardi, Ayelet, et al.
Publicado: (2021)

Brain cell type specific proteomics approach to discover pathological mechanisms in the childhood CNS disorder mucolipidosis type IV
por: Sangster, Madison, et al.
Publicado: (2023)

Membrane traffic and turnover in TRP-ML1–deficient cells: a revised model for mucolipidosis type IV pathogenesis
por: Miedel, Mark T., et al.
Publicado: (2008)

The Dictyostelium Model for Mucolipidosis Type IV
por: Allan, Claire Y., et al.
Publicado: (2022)

Autophagic dysfunction in mucolipidosis type IV patients
por: Vergarajauregui, Silvia, et al.
Publicado: (2008)

Unique molecular signature in mucolipidosis type IV microglia
por: Cougnoux, Antony, et al.
Publicado: (2019)

The first genetically confirmed Japanese patient with mucolipidosis type IV
por: Saijo, Harumi, et al.
Publicado: (2016)

Systematic Screens for Proteins That Interact with the Mucolipidosis Type IV Protein TRPML1
por: Spooner, Ellen, et al.
Publicado: (2013)

Transition metals activate TFEB in overexpressing cells
por: Peña, Karina A., et al.
Publicado: (2015)

Neurologic Abnormalities in Mouse Models of the Lysosomal Storage Disorders Mucolipidosis II and Mucolipidosis III γ
por: Idol, Rachel A., et al.
Publicado: (2014)

Neuropathophysiology, Genetic Profile, and Clinical Manifestation of Mucolipidosis IV—A Review and Case Series
por: Jezela-Stanek, Aleksandra, et al.
Publicado: (2020)

The mucolipidosis IV Ca(2+) channel TRPML1 (MCOLN1) is regulated by the TOR kinase
por: Onyenwoke, Rob U., et al.
Publicado: (2015)

Correction: Neurologic Abnormalities in Mouse Models of the Lysosomal Storage Disorders Mucolipidosis II and Mucolipidosis III γ
Publicado: (2014)

Case Report: Mucolipidosis II and III Alpha/Beta Caused by Pathogenic Variants in the GNPTAB Gene (Mucolipidosis)
por: Mao, Shao-Jia, et al.
Publicado: (2022)

Probing pathomechanisms of mucolipidosis II in fish
Publicado: (2012)

Hip Morphology in Mucolipidosis Type II
por: Ammer, Luise Sophie, et al.
Publicado: (2020)

THE ACCUMULATION OF IRON IN TUBERCULOUS AREAS : IV. THE EFFECT OF FERRIC CHLORIDE ON THE COURSE OF TUBERCULOSIS IN REINFECTED RABBITS
por: Menkin, Valy
Publicado: (1934)

Effectiveness and safety of ferric carboxymaltose compared to iron sucrose in women with iron deficiency anemia: phase IV clinical trials
por: Naqash, Amreen, et al.
Publicado: (2018)

Ferric Iron Reduction in Extreme Acidophiles
por: Malik, Luise, et al.
Publicado: (2022)

Mucolipidosis Type IV in Omani Families with a Novel MCOLN1 Mutation: Search for Evidence of Founder Effect
por: Al-Alawi, Badriya, et al.
Publicado: (2022)

High-Dose Intravenous Iron with Either Ferric Carboxymaltose or Ferric Derisomaltose: A Benefit-Risk Assessment
por: Boots, Johannes M. M., et al.
Publicado: (2022)

Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal microbiome in female iron-deficient anemic mice
por: Rieg, Timo, et al.
Publicado: (2023)

TPC2 rescues lysosomal storage in mucolipidosis type IV, Niemann–Pick type C1, and Batten disease
por: Scotto Rosato, Anna, et al.
Publicado: (2022)

Mucolipidosis II: first report from Saudi Arabia
por: Alfadhel, Majid, et al.
Publicado: (2013)

Mucolipidosis type III, a series of adult patients
por: Oussoren, Esmee, et al.
Publicado: (2018)

Diagnosis of Mucopolysaccharidoses and Mucolipidosis by Assaying Multiplex Enzymes and Glycosaminoglycans
por: Arunkumar, Nivethitha, et al.
Publicado: (2021)

Treatment of iron deficiency and iron deficiency anemia with intravenous ferric carboxymaltose in pregnancy
por: Froessler, Bernd, et al.
Publicado: (2018)

Evaluation of Ferric and Ferrous Iron Therapies in Women with Iron Deficiency Anaemia
por: Berber, Ilhami, et al.
Publicado: (2014)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia
por: Friedrisch, João Ricardo, et al.
Publicado: (2015)

Paracoccidioides spp. ferrous and ferric iron assimilation pathways
por: Bailão, Elisa Flávia L. C., et al.
Publicado: (2015)

Ferric Carboxymaltose as Treatment in Women with Iron-Deficiency Anemia
por: Seid, Melvin H., et al.
Publicado: (2017)

Intravenous ferric derisomaltose for the treatment of iron deficiency anemia
por: Auerbach, Michael, et al.
Publicado: (2021)

Flavobacterium columnare ferric iron uptake systems are required for virulence
por: Conrad, Rachel A., et al.
Publicado: (2022)

Quaternary diagnostics scheme for mucolipidosis II and detection of novel mutation in GNPTAB gene
por: Essawi, Mona L., et al.
Publicado: (2021)

Cost-Minimization Analysis Favours Intravenous Ferric Carboxymaltose over Ferric Sucrose for the Ambulatory Treatment of Severe Iron Deficiency
por: Calvet, Xavier, et al.
Publicado: (2012)

Intravenous ferric carboxymaltose for the treatment of iron deficiency anemia: Letter to Editor
por: Kanshaiym, Sakiyeva, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h1h23bnqohalt60l5tqmah2oq4